Welcome to Entry Card of Lysosomal Enzymes

Details of RareLED ID Assay_1022

Primary information
GENE	GAA
NUMBER OF ASSAY	143
ASSAY IDs	2113 2100 2242 1466 2112 1467 2101 2107 37266 37395 37291 37290 37289 540341 391607 317577 2111 2110 997 540361 2109 467032 467031 467037 467036 467035 467034 467033 37396 241237 241202 240897 240863 228869 391608 219606 488834 2115 2577 343500 235284 37286 37284 37272 467038 383183 219607 37275 219609 36704 705433 1293688 40163 40144 40425 424218 402238 1180481 1235896 37407 36803 40292 766631 705436 705434 705424 536220 1331252 402241 400761 1096563 1095890 1083638 400755 768173 768167 768166 1293689 342799 403083 724304 592240 466672 37276 36805 553257 437995 342811 1198747 1198746 1198741 1198740 766635 766632 671263 671262 671261 638442 536213 40422 37132 37114 1308876 402242 289001 647236 641146 590735 397845 342793 338542 1250858 1250857 1250854 1235933 1181386 763818 763816 738372 718832 711104 710939 696532 673422 673417 673416 594099 593351 578319 5
Assay Name	1. Confirmation of Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,2. qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,3. qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,4. qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,5. qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,6. qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,7. qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,8. qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,9. Inhibition of alpha-glucosidase activity,10. Inhibitory activity measured against alpha-glucosidase of rat liver ER glucosidase II by colorimetric assay using the D-glucose oxidase-peroxidase method,11. Inhibitory activity measured against alpha-glucosidase of rat intestinal sucrase by colorimetric assay using the D-glucose oxidase-peroxidase method,12. Inhibitory activity measured against alpha-glucosidase of rat intestinal maltase by colorimetric assay using the D-glucose oxidase-peroxidase method,13. Inhibitory activity measured against alpha-glucosidase of rat intestinal isomaltase by colorimetric assay using the D-glucose oxidase-peroxidase method,14. Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease: Glucocerebrosidase Counter Screen,15. Inhibition of Bacillus stearothermophilus alpha-glucosidase,16. Inhibition of maltase,17. Confirmation of Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate Using an Alternate Red Fluorescent Susbtrate,18. Confirmation of Inhibitors and Activators of Purified Human alpha-Glucosidase Using an Alternate Red Fluorescent Susbtrate,19. Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,20. Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease: Alpha-Galactosidase Counter Screen,21. Confirmation of Inhibitors and Activators of Purified Human alpha-Galactosidase,22. Inhibition of Bacillus stearothermophilus alpha-glucosidase assessed as p-nitrophenol release by colorimetry,23. Inhibition of Saccharomyces cerevisiae alpha-glucosidase assessed as p-nitrophenol release by colorimetry,24. Cytotoxicity against human MOLT3 cells by XTT assay,25. Cytotoxicity against human A549 cells after 4 days by MTT assay,26. Cytotoxicity against HuCCa1 cells after 4 days by MTT assay,27. Cytotoxicity against human HepG2 cells after 4 days by MTT assay,28. Inhibition of aromatase,29. Inhibitory activity measured against alpha-glucosidase of rat liver lysosomal by colorimetric assay using the D-glucose oxidase-peroxidase method,30. Inhibitory concentration against beta-galactosidase of bovine liver,31. Inhibitory concentration against beta-galactosidase of bovine liver,32. Inhibitory concentration against human beta-galactosidase,33. Inhibitory concentration against human alpha-mannosidase,34. Free radical scavenging assessed as 50% reduction in DPPH absorbance (516 nm),35. Inhibition of Saccharomyces cerevisiae alpha-glucosidase,36. Inhibitory potency for brewer's yeast alpha-glucosidase in 0.01 mM EDTA, 0.01 mM PIPES and 0.2 M NaOAc at pH 6.5.,37. qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease: Alpha-Glucosidase Counterscreen for Probe SAR,38. Confirmation of Inhibitors and Activators of Purified Human alpha-Glucosidase,39. qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease: Alpha-Glucosidase Counterscreen,40. Inhibition of rat intestinal maltase,41. Free radical scavenging assessed as ABTS (2,2'-azinobis-(3-ethyl benz) thiazoline-6-sulfonic acid) color change,42. Concentration that causes 50% inhibition of mammalian alpha-glucosidase (maltase) was determined in rat intestine,43. Concentration that causes 50% inhibition of mammalian alpha-glucosidase (lysosomal) was determined in rat liver,44. Inhibition of mammalian alpha-glucosidase (lysosomal) was determined in bovine liver,45. Cytotoxicity against human HL60 cells by XTT assay,46. Inhibition of Saccharomyces sp. alpha-glucosidase,47. Inhibitory potency for brewer's yeast alpha-glucosidase in 0.1 M sodium phosphate buffer at pH 6.55.,48. Tested in vitro for the inhibition constant against human lysosomal alpha-glucosidase,49. Compound was evaluated for inhibition of alpha-glucosidase from yeast(sigma G 7256).,50. Tested for inhibitory constant against yeast alpha-glucosidase,51. Inhibition of wild type recombinant GAA preincubated for 5 mins measured after 45 mins using red-shifted dye by fluorescence assay,52. Inhibition of baker's yeast alpha-glucosidase using pNPG as substrate by spectrophotometry,53. Tested for competitive inhibition of bovine liver beta-galactosidase,54. Concentration that causes 50% inhibition of mammalian cytosolic beta-galactosidase was determined in bovine liver,55. Inhibition of Beta-glucosidase activity.,56. Inhibition of rat intestinal alpha-glucosidase,57. Inhibition of rat intestinal maltase by spectrophotometry,58. Inhibition of Saccharomyces cerevisiae alpha-glucosidase,59. Inhibition of alpha-glucosidase (unknown origin) pre-incubated for 20 mins before p-nitrophenyl glycoside substrate addition,60. Compound was tested for inhibition of alpha-glucosidase from yeast.,61. Inhibitory activity was determined against baker's yeast Alpha-Glucosidase,62. Inhibitory concentration of compound against Beta-glucosidase from Almond,63. Uncompetitive inhibition of Saccharomyces cerevisiae alpha-glucosidase using maltose as substrate by Cornish-Bowden plot analysis,64. Inhibition of human recombinant GAA assessed as hydrolysis of bovine liver glycogen by Amplex red oxidase assay,65. Inhibition of wild type recombinant GAA preincubated for 5 mins measured after 45 mins using blue-shifted dye by fluorescence assay,66. Binding affinity at wild type recombinant NT-495 labelled GAA incubated for 15 mins by microscale thermophoresis assay,67. Competitive inhibition of yeast alpha-glucosidase after 90 mins by Lineweaver-Burke plot analysis,68. Inhibition of Saccharomyces cerevisiae alpha-glucosidase using PNPG as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins,69. Inhibition of human placental beta-glucocerebrosidase by spectrophotometry,70. Inhibition of Wistar rat liver lysosomal alpha-glucosidase,71. Inhibition of rat intestinal alpha-glucosidase using para-nitrophenyl-alpha-D-glucopyranoside as substrate incubated for 5 min prior to substrate addition measured after 5 min by spectrophotometric analysis,72. Inhibition ofRattus norvegicus alpha-glucosidase isolated from intestine using PNPG as substrate incubated for 15 min prior to substrate addition measured after 15 min by spectrophotometric analysis,73. Inhibition of rat intestinal alpha-glucosidase using p-nitrophenyl- alpha-D-glucopyranoside as substrate preincubated for 5 min before addition of substrate measured after 10 min,74. Inhibition of Wistar rat intestinal maltase,75. Inhibition of rat intestine maltase using maltose as substrate incubated for 10 mins prior to substrate addition measured after 40 mins by glucose oxidase colorimetric method,76. Competitive inhibition of rat intestine maltase using maltose as substrate by Lineweaver-Burk plot analysis,77. Non-competitive inhibition of rat intestine maltase using maltose as substrate by Lineweaver-Burk plot analysis,78. Uncompetitive inhibition of baker's yeast alpha-glucosidase using pNPG as substrate by Cornish-Bowden plot analysis,79. Inhibition of human lysosomal alpha-glucosidase,80. Inhibition of alpha-glucosidase,81. Inhibition of pure alpha-glucosidase (unknown origin) assessed as para-nitrophenol release at 420 nm OD,82. Inhibition of yeast alpha-glucosidase assessed as inhibition of p-nitrophenyl-alpha-D-glucopyranoside substrate hydrolysis after 35 mins by spectroscopy,83. Inhibition of lysosomal alpha-glucosidase by HPLC,84. The compound was tested for its inhibitory activity against Alpha-glucosidase,85. Inhibitory activity against alpha-glucosidase of yeast,86. Inhibition of maltase in mouse intestinal input by glucose release assay,87. Inhibition of human lysosomal alpha glucosidase,88. Inhibition of maltase in human Caco-2 cell model system after 2 hrs,89. Mixed type inhibition of Saccharomyces cerevisiae alpha-glucosidase using 4-NPGP substrate assessed as equilibrium constant for binding to enzyme-4-NPGP complex by measuring reduction in 4-nitrophenol release pre-incubated for 10 mins before substrate addition by Dixon plot analysis,90. Mixed type inhibition of Saccharomyces cerevisiae alpha-glucosidase using 4-NPGP substrate assessed as equilibrium constant for binding to enzyme by measuring reduction in 4-nitrophenol release pre-incubated for 10 mins before substrate addition by Dixon plot analysis,91. Inhibition of Saccharomyces cerevisiae alpha-glucosidase,92. Inhibition of Saccharomyces cerevisiae alpha-glucosidase using 4-NPGP substrate assessed as reduction in 4-nitrophenol release pre-incubated for 10 mins before substrate addition by microplate reader based assay,93. Inhibition of Saccharomyces cerevisiae alpha-glucosidase using pNPG as substrate at 100 uM preincubated for 20 mins followed by substrate addition measured after 45 mins,94. Uncompetitive inhibition of Saccharomyces cerevisiae alpha-glucosidase using pNPG as substrate by Cornish-Bowden plot analysis,95. Competitive inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate by Lineweaver-Burk plot and Dixon plot analysis,96. Mixed type inhibition of Saccharomyces cere
ACTIVITY	Substance BioActivity: 57 Active, 7 Activity <= 1 µM, 423 Tested Substance BioActivity: 1169 Active, 16 Activity <= 1 µM, 304269 Tested Substance BioActivity: 715 Active, 924 Activity <= 1 µM, 199303 Tested Substance BioActivity: 10 Active, 924 Activity <= 1 µM, 199303 Tested Substance BioActivity: 16 Active, 90 Activity <= 1 µM, 236748 Tested Substance BioActivity: 99 Activity <= 1 µM, 229459 Tested Substance BioActivity: 299 Active, 528 Activity <= 1 µM, 326770 Tested Substance BioActivity: 19 Active, 89 Activity <= 1 µM, 239498 Tested Substance BioActivity: 1 Active, 18 Tested Substance BioActivity: 1 Active, 3 Tested Substance BioActivity: 7 Active, 3 Activity <= 1 µM, 8 Tested Substance BioActivity: 7 Active, 2 Activity <= 1 µM, 7 Tested Substance BioActivity: 2 Active, 1 Activity <= 1 µM, 3 Tested Substance BioActivity: 29 Tested Substance BioActivity: 21 Active, 7 Activity <= 1 µM, 26 Tested Substance BioActivity: 1 Tested Substance BioActivity: 58 Active, 4 Activity